For the better part of a decade, the default advice handed to medtech founders planning a first-in-human (FIH) study fit in three words: go to Australia. The pitch was seductive and, for a while, mostly true. A notification-based regulatory pathway that could clear in weeks. A 43.5% refundable R&D tax offset. For a cash-constrained startup,…
